GemOral® (D07001) is an oral softgel formulation of gemcitabine developed by InnoPharmax, Inc. using the Company’s proprietary oral drug delivery platform, OralPAS®. Designed to move beyond the conventional intravenous administration of gemcitabine, GemOral® (D07001) is being developed to support a low-dose, regular dosing approach known as metronomic chemotherapy. By enabling an oral dosing strategy, the program may help reduce the treatment burden associated with repeated infusion-center visits and support the development of all-oral regimens combining gemcitabine with other oral anticancer agents.
  GemOral® (D07001) has been granted Orphan Drug Designation by the U.S. FDA for the treatment of biliary tract cancer. For patients with advanced biliary tract cancer whose disease has progressed after prior therapy, treatment options remain limited and the unmet medical need remains high. If successfully developed and approved, GemOral® (D07001) may offer an additional treatment option for this patient population.
  According to Research and Markets, the global biliary tract cancer market was valued at approximately USD 3.86 billion and is expected to reach USD 6.78 billion by 2032, representing a compound annual growth rate of approximately 8%. Market growth is expected to be driven by increasing disease incidence, new drug approvals, and the growing role of personalized medicine and biomarker-based diagnostics.
  The global Phase 3 clinical trial is a multinational, multicenter, randomized, double-blind, placebo-controlled study evaluating GemOral® (D07001) in combination with capecitabine in patients with advanced biliary tract cancer. Following the enrollment of the first patient, InnoPharmax will continue working with investigators, clinical trial sites, CROs, and international partners to advance patient enrollment and trial execution.
  GemOral® (D07001) is currently under clinical development and has not been approved by any regulatory authority. Its safety and efficacy remain subject to further clinical evaluation.
  
  Linkedin